High-risk meds and safety

paper dolls holding hands

Patient safety in regard to high-risk medicines is a new focus for two organisations who have joined together to help

Australian clinical pharmacists have an unprecedented opportunity to improve patient safety in the use of high-risk medicines through a new $30,000 Juno Pharmaceuticals research grant, the SHPA says.

The grant has almost doubled the pool of funding available to date through SHPA’s National Translational Research Collaborative (NTRC).

The $30,000 Emerging Researcher Grant was jointly announced by SHPA and Juno, a local Australian and New Zealand hospital and specialty post-patent pharmaceutical leader, to support the next generation of pharmacy researchers, reinforcing both organisations’ commitment to innovative thinking and advancing pharmacy practice.

Chief Executive Kristin Michaels says SHPA and Juno are proud to join forces to support emerging researchers in their quest to improve the safe use of high-risk medicines.

“Perfect for emerging pharmacy researchers with previous proven experience, the Emerging Researcher Grant provides a ‘next step’ towards supporting future, larger research projects while funding initiatives that directly improve patient safety in current practice,” she says.

Expressions of interest are open until 5.00pm Sunday 29 July, giving emerging researchers time to submit a literature review and research gap identification focusing on a number of key areas, prior to research proposal submissions for successful applicants. View timeline, application criteria and other information at NTRC online.

Ms Michaels says with the pool of research grants swelling to $80,000 since its launch and applications entered from around the country, SHPA’s NTRC is connecting and supporting Australian pharmacy research individuals and organisations to translate innovative ideas into meaningful improvements for patients.

Previous Research Roundup
Next Samoa pulls MMR vax program after infant deaths

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply